We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
-5.88%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$315M
AUM Growth
+$48.5M
Cap. Flow
+$47.4M
Cap. Flow %
15.08%
Top 10 Hldgs %
69.9%
Holding
69
New
7
Increased
7
Reduced
7
Closed
20

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$30M
2
SNY icon
Sanofi
SNY
+$15.9M
3
COR icon
Cencora
COR
+$14.2M
4
SNN icon
Smith & Nephew
SNN
+$5.85M
5
SKIN icon
SkinHealth Systems
SKIN
+$3.75M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$10.4M
2
BIIB icon
Biogen
BIIB
+$7.32M
3
MDT icon
Medtronic
MDT
+$7.18M
4
SGHT icon
Sight Sciences
SGHT
+$6.52M
5
NTUS
Natus Medical Inc
NTUS
+$6.26M

Sector Composition

Rank Sector Weight
1 Healthcare 63.89%
2 Financials 7.31%
3 Consumer Staples 2.47%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHC icon
26
PUT
Bausch Health
BHC
$2.32B
$1.94M 0.62%
281,200
-761,500
-73% -$5.29M
RCOR
27
DELISTED
Renovacor, Inc.
RCOR
$1.85M 0.59%
735,908
– –
MRUS
28
DELISTED
Merus
MRUS
$1.76M 0.56%
87,953
– –
AFMD
29
DELISTED
Affimed
AFMD
$1.69M 0.54%
82,107
– –
ISEE
30
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.55M 0.49%
86,400
– –
TYRA icon
31
Tyra Biosciences
TYRA
$1.6B
$1.34M 0.42%
152,159
– –
SVRA icon
32
Savara
SVRA
$1.13B
$1.33M 0.42%
856,428
– –
ANIP icon
33
ANI Pharmaceuticals
ANIP
$1.82B
$1.29M 0.41%
40,000
– –
MBRX icon
34
Moleculin Biotech
MBRX
$2.85M
$1.1M 0.35%
2,765
– –
IDYA icon
35
IDEAYA Biosciences
IDYA
$3.51B
$1.04M 0.33%
+70,000
New +$909K
FUSN
36
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$784K 0.25%
260,448
– –
CNTB
37
Connect Biopharma Holdings
CNTB
$132M
$771K 0.25%
597,678
– –
ASLN
38
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$761K 0.24%
31,769
– –
ELEV
39
DELISTED
Elevation Oncology
ELEV
$406K 0.13%
359,731
– –
NXTC icon
40
NextCure
NXTC
$20.4M
$358K 0.11%
10,833
– –
CMAX
41
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$218K 0.07%
1,025
– –
VINC
42
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$141K 0.04%
5,102
– –
NBSE
43
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$102K 0.03%
12,972
-32,350
-71% -$535K
NYXH
44
Nyxoah
NYXH
$141M
$101K 0.03%
16,110
– –
CLNN icon
45
PUT
Clene
CLNN
$68.5M
$64K 0.02%
+1,135
New +$75.2K
HUMAW icon
46
Humacyte Inc Warrant
HUMAW
$1.09M
$58K 0.02%
49,998
– –
RCOR.WS
47
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$37K 0.01%
400,000
– –
NGNE icon
48
Neurogene
NGNE
$705M
$25K 0.01%
1,916
– –
CMAXW
49
DELISTED
CareMax, Inc. Warrant
CMAXW
$23K 0.01%
12,808
– –
ARDX icon
50
Ardelyx
ARDX
$1.21B
– –
-692,357
Closed -$408K
1
2
3

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Sio Capital Management held 69 positions worth $315M, up 18% from $266M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sio Capital Management deployed $47.4M of net new capital in Q3 2022, opening 7 new positions and adding to 7 existing holdings. Its largest new stake was GSK: 790,600 shares worth $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 84% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Inari Medical, Inc. Common Stock, an estimated $4.09M trimmed.

  • Sio Capital Management's largest Q3 2022 buy was GSK: 790,600 shares worth $23.3M.
  • Sio Capital Management added most to Cencora in Q3 2022, an estimated $14.2M increase.
  • Sio Capital Management's biggest Q3 2022 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $4.09M.
  • Sio Capital Management fully exited HCA Healthcare in Q3 2022, selling an estimated $10.4M.
  • Sio Capital Management's ten largest holdings make up 70% of its $315M portfolio in Q3 2022.
  • Sio Capital Management opened 7 new positions and closed 20 in Q3 2022.
  • Sio Capital Management's portfolio value rose 18% quarter-over-quarter to $315M.

Based on Sio Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.